Abcellera posts ABCL635 Phase 2 clinical update presentation on menopause hot flashes

• Abcellera released a Phase 2 clinical update presentation for ABCL635 in moderate-to-severe menopausal vasomotor symptoms.
• Week 4 data showed an 83% reduction in moderate-to-severe VMS frequency vs. 33% for placebo; placebo-adjusted difference 50%.
• VMS severity score fell 58% vs. 12% for placebo at week 4; placebo-adjusted difference 46%.
• Safety summary showed no serious or grade 3+ adverse events in the ABCL635 arm; one mild transaminase increase resolved within one week.
• Next steps include completing 12-week follow-up to support dose selection, then regulatory talks on late-stage development in menopause and oncology settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.